Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention provides compositions and methods for eliciting heterologous protective immunity in animals against Leptospira spp. The Leptospira spp. immunoprotective peptides disclosed herein elicit protective immunity against subsequent challenge or exposure to at least two Leptospira spp. serovars.

Abstract: The invention relates to a recombinant Mycobacterium cell for use as an immunotherapeutic agent in the treatment of cancer, particularly in the treatment of solid tumors. More particularly, the invention relates to the immunotherapy of bladder carcinoma.

Abstract: Cold spot genes of S. pneumoniae are disclosed that encode surface proteins that are universally conserved among known strains and have exceptionally low incidence of allelic variation. Cold spot polypeptides encoded by the genes that are antigenic on the S. pneumoniae cells on which they are expressed are candidates for immunogenic compositions capable of eliciting antibodies able to react with all or nearly all strains of S. pneumoniae, thus providing an improvement over currently available S. pneumoniae vaccines that protect inoculated individuals against a maximum of about 23 of the 94 or so known serotypes of S. pneumonia.

Abstract: Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.

Abstract: The present invention relates to methods for inducing an immune response to influenza in a subject comprising administering a nanoemulsion vaccine composition comprising an influenza immunogen or protein.

Abstract: The present invention provides a vaccine containing virus-like particles derived from virus particles having an envelope, in which a lipid-component content of the virus-like particles is reduced relative to a lipid-component content of the virus particles.

Abstract: Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine encoding mosaic HIV antigens.

Abstract: Mixed allergen compositions of two or more different allergens are provided. In some instances, the mixed allergen compositions include: a nut allergen; an animal allergen; and at least one of: a non-nut plant allergen; a biotic agent; and a vitamin. Also provided are methods of administering the mixed allergen compositions to a subject. The mixed allergen compositions find use in a variety of applications, including health maintenance, immune balance, gut balance, immune support, health improvement and therapeutic applications.

Abstract: Mixed allergen compositions of one, two or more different allergens are provided. In some instances, the mixed allergen compositions include: a nut allergen; an animal allergen; and at least one of: a non-nut plant allergen; a biotic agent; and a vitamin. Also provided are methods of administering the mixed allergen compositions to a subject. The mixed allergen compositions find use in a variety of applications, including health maintenance, immune balance, gut balance, immune support, health improvement and therapeutic applications.

Abstract: The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure describes genetic engineering of E. coli to create mutant O-antigen ligase, as well as novel lipopolysaccharide molecules resulting from that genetic engineering. Methods for using those novel molecules are also described.

Abstract: The present invention Provides composition and method for stimulating immune responses against antigens without using conventional adjuvants (such as aluminum salt adjuvants, oil-in-water emulsion adjuvants, toll-like receptor agonist adjuvants, and the like). The composition contains p14.7 protein and an antigen to which the stimulated illumine responses are desired. The p14.7 protein functions as an adjuvant so that the immune responses to the antigen stimulated by the composition comprising p14.7 protein and the antigen are greater than the immune responses stimulated by the antigen alone. The current invention also provides a method for producing thermostable vaccines and a simple strategy for avoiding vaccine cold-chain maintenance by lyophilization.

Abstract: This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.

Abstract: The invention provides a method of treating a patient having target cells that express FcyRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcyRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcyRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcyRIIb.

Abstract: The present invention provides stable pharmaceutical antibody formulations, including liquid drug product formulations and lyophilized drug product formulations, comprising an IgG4 binding agent and a citrate buffer, wherein the pH of the formulation is at or below both pH 6 and the pI of the binding agent. The formulations can be used in the treatment of chronic bowel diseases or rheumatoid arthritis.

Abstract: Herein are provided derivatized hyperbranched polyglycerols (“dHPGs”). The dHPG comprises a core comprising a hyperbranched polyglycerol derivatized with C1C20 alkyl chains and a shell comprising at least one hydrophilic substituent bound to hydroxyl groups of the core, wherein the hyperbranched polyglycerol comprises from about 1 to about 200 moles of the at least one hydrophilic substituent. The dHPGs are for use as agents for the delivery of a drug or other biologically active moiety to the urinary tract, the digestive tract, the airways, the vaginal cavity and cervix and the peritoneal cavity to treat indications such as cancer, which may be useful in the treatment of or the manufacture of a medicament, in the preparation, of a pharmaceutical composition for the treatment of cancer, as a pre-treatment or co-treatment to improve drug uptake in a tissue. Furthermore, there are provided methods of making dHPGs.

Abstract: The present invention provides a topical preparation for treating hyperhidrosis, comprising water, an anticholinergic drug, and one or more salts selected from the group consisting of lactate, tartrate, acetate and phosphate. Such a topical preparation comprises the above certain salt, thereby facilitating the accumulation of the anticholinergic drug in skin appendages.

Abstract: The present invention relates to a liquid composition which comprises, in an aqueous medium, one or more protein(s) and one or more solubilizing agent(s) chosen from the group consisting of anionic compounds of non-saccharide structure, said structure of which contains at least one aromatic nucleus comprising at least 6 ring members (6 atoms) and at least one carboxylic acid group in salified form, and which has, in its acid form, a molar mass of between 130 and 500 g/mol. It also relates to the use of said solubilizing agent(s) for preparing compositions according to the invention.

Abstract: The present invention provides stable liquid or semi-solid pharmaceutical compositions of apomorphine, more particularly composition comprising apomorphine and an organic acid, which are useful in treatment of neurological or movement diseases or disorders, e.g., Parkinson's disease, or conditions associated therewith.

Abstract: The present disclosure relates to a method for preparing a novel sugar alcohol with a modified, that is, increased or decreased surface area and/or porosity while having flowability as a solid phase, and also to a sugar alcohol prepared by the preparing method or a pharmaceutical composition, a cosmetic composition, a food composition and a feed composition, comprising the sugar alcohol as a carrier. According to the present disclosure, the method for preparing a sugar alcohol comprises: (A) reacting the sugar alcohol in a solid state with a solvent (S), wherein the solid state sugar alcohol is not dissolved by the solvent (S) and is reacted with the solvent (S) as a solid dispersion; and (B) removing the solvent (S) therefrom. The sugar alcohol prepared by the preparing method of the present disclosure has a modified, that is, increased or decreased surface area and/or porosity in comparison with a conventional sugar alcohol.

Abstract: Provided is a flavor modifying composition including a blend of a water soluble filler including plant fibers; and at least one sucrose substitute of natural source, wherein said flavor modifying composition includes at least 90% w/w of the filler, the amount being determined when said composition is in dry form; and said flavor modifying composition is water soluble. The flavor modifying composition is particularly effective in enhancing sweet taste and/or aroma of a product. Further provided are products including the flavor modifying composition.

Abstract: The invention provides methods for making such formulations and methods of using such formulations. The invention further provides methods of reducing polysorbate degradation, methods of reducing the amount of visible and sub-visible particles in an aqueous formulation, and methods of disaggregating polysorbate degradation products comprising adding a cyclodextrin to a formula comprising polysorbate and a polypeptide. The invention also provides aqueous formulations comprising a polypeptide, a polysorbate, and a cyclodextrin with reduced polysorbate degradation.

Abstract: The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof as a cationic lipid, and the like.

Abstract: The invention relates to novel derivatives of thapsigargin that are chemically modified with a group that targets a cell surface-expressed receptor, and pharmaceutical preparations thereof. The invention further relates to methods of treating diseases such as cancer using the compounds of the invention.

Abstract: A filler material of a thermoset resin of a diacid/polyol, such as PGS is provided. The filler useful in forming composites, such as those in which the filler and a resin matrix are of the same material to provide a homogenous polymeric composition. Composites in which at least one of the matrix, the filler or both are PGS are also provided. Methods of forming such filler materials and composites are also disclosed. The composites allow extrusion process to form articles from materials that would not otherwise be capable of being extruded.

Abstract: It is provided a polyglycerol derivative, comprising a dendritic polyglycerol backbone and at least one substituent in the nature of a covalently bound negatively charged group chosen from the group consisting of sulfates, sulfonates, phosphates, phosphonates, bisphosphonates, carboxylates and combinations thereof. The substituent is bound to the polyglycerol backbone via a linker, the linker being chosen from the group consisting of moieties being or comprising a carbamate group, an ester group, an orthoester group, an amide group, a disulfide bridge group, an acetal group, an imine group and combinations thereof.

Abstract: The present invention relates generally to methods of treating cancer with arginine deiminase, and in particular pegylated arginine deiminase.

Abstract: A conjugate represented by general formula (I), wherein R0 is a C1-6 alkyl, B is an anesthetic, and A is a linking group, and a quaternary ammonium salt is formed at the linking position between B and R0. The conjugate has a prolonged analgesic effect, and can be used in postoperative analgesia or treatment for chronic pain.

Abstract: The present invention provides compounds and a method for the targeted delivery of Mitochondrial Angiotensin Receptor Blockers (MARBs) to the Mitochondrial Angiotensin System (MAS) for the treatment of diseases caused by angiotensin-related mitochondrial dysfunction. The compounds include a mitochondrial targeting signal, a residue of a drug molecule, a functional moiety, and a scaffold moiety.

Abstract: Compositions and methods for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) are described. In particular, multivalent vaccines containing E. coli antigen polysaccharide covalently bound to a exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein that can withstand multiple environmental stresses are described.

Abstract: A nanostructure comprises a MOX NP and a bidentate ligand on a surface of the MOX NP. A cancer recognition molecule is covalent coupled to the surface of the MOX NP via the bidentate ligand. A biocatalyst is also coupled to the surface of the MOX nanoparticle via the bidentate ligand. The cancer recognition molecule includes a structure configured to selectively recognize a corresponding antigen on a surface of a cancer cell and bind to the antigen. The biocatalyst is structured to selectively catalyze the oxidation of a light emitting compound to produce photons. The photons transform the MOX NPs into an excited state such that the MOX NPs generate reactive oxygen species (ROS) in the vicinity of the cancer cells in the excited state. The reactive oxygen species lyse or cause apoptosis in the cancer cells in situ. The biocatalyst includes luciferase and the light emitting compound includes luciferin.

Abstract: A method for treating a burn, lesion, lacuna, or wound comprising contacting the burn, lesion, or wound with a chitosan-functionalized silica sphere (“CHI-HSS”). Chitosan-functionalized silica spheres and pharmaceutical compositions containing them.

Abstract: Embodiments of the invention provide methods of creating clinical models for different forms of metastatic cancer. The methods may include obtaining samples from subjects with metastatic cancer, determining an allelic status of one or more markers in the samples (e.g., creating a molecular profile of the subject's cancer), and using model organisms with subject-derived xenografts for treatment selection.

Abstract: Compositions and methods for assessing blood vessels and organs of the body are disclosed herein, specifically methods for assessing the vasculature of the eye.

Abstract: A contrast agent having a contrast protein have contrast properties and at least one targeting moiety, wherein the at least one targeting moiety is operatively linked to or incorporated within the contrast protein. Methods for targeting contrast agents and for preparing such agents are included.

Abstract: A method for preparing a radiopharmaceutical and, specifically, a method for preparing an organic fluoride-aliphatic compound usable as a radiopharmaceutical, a method for purifying the prepared organic fluoride-aliphatic compound, and a method for preparing a radiopharmaceutical by using a cassette comprising a backdraft preventing reaction container. A method for preparing an organic fluorinated aliphatic compound includes allowing a fluorine salt to react with a leaving group-containing aliphatic compound by using a multifunctional solvent represented by the following Chemical Formula 1 to obtain an aliphatic compound labeled with [18F] fluoride substituting for the leaving group. The organic fluoride-aliphatic compound can be prepared and purified through even a simple process at high yield, high efficiency, and high purity, and the radiopharmaceutical can be safely prepared without damage to a synthetic apparatus.

Abstract: A new approach to targeting imaging agents to macrophage-rich sites of interest is disclosed. Compositions of the invention are rHDL and HDL-like liposomal compositions, protein constituents of which, apolipoproteins A-I and/or A-II or fragments thereof are used not only as structural but also as targeting agents. This is achieved by certain controlled chemical or enzymatic modification of apolipoproteins A-I or A-II or fragments thereof. Such modification converts these apolipoproteins to substrates for macrophage scavenger receptors and results in the improvement of contrast agent-(HDL/modified apolipoprotein)-particle association with macrophages and/or absorption (uptake) by macrophages when compared to that of the contrast agent-(HDL/apolipoprotein)-particle constructed with non-modified naturally occurring apo A-I.

Abstract: A sterilizing apparatus is disclosed. A sterilizing apparatus according to one embodiment comprises: a cover main body unit having an accommodation space formed therein so as to accommodate a device to be sterilized, wherein the accommodation space is open toward a bottom surface on which the device to be sterilized is disposed; an ultraviolet light emitting diode provided on a surface facing the bottom surface of the cover main body unit, and turned on so as to emit ultraviolet rays toward the accommodation space; a power supply unit for supplying power to the ultraviolet light emitting diode so as to turn on the ultraviolet light emitting diode; and a control unit for controlling an operation of the power supply unit.

Abstract: A system for providing ultraviolet treatment to light absorbing liquids, such as biological liquids in a medical instrument, is disclosed. The system can include an ultraviolet impenetrable housing configured to enclose a portion of the medical instrument containing the biological fluid. At least one ultraviolet radiation source is integrated within the housing that emits ultraviolet radiation towards the medical instrument and the biological fluid. A control unit is configured to direct the ultraviolet radiation source to treat the biological fluid with ultraviolet radiation.

Abstract: A sterilizer may include: a first pipe having an inner wall with a light reflecting property; a second pipe disposed in the first pipe so as to pass fluid therethrough and formed of a light transmitting material; and a plurality of UV LEDs arranged on the inner wall of the first pipe and configured to irradiate sterilization UV light onto the fluid.

Abstract: A gastro-intestinal (GI) scope device for use in the disinfection of a patient's colon including a gastro-intestinal (GI) scope having an insertion tube and a universal cord, an ultraviolet (UV) light assembly, and a UV light sleeve assembly, wherein the UV light assembly includes a power source, a UV light box operatively connected to the power source, and a UV light source operatively connected to the UV light box, wherein the UV light source is located within an interior of the insertion tube and the UV light sleeve assembly is located on an end of the insertion tube in order to disinfect a patient's colon.

Abstract: Alkaline in-use solutions that may be used to disinfect and/or sanitize hard surfaces and which may act as anti-biofilm agents, comprise a disinfectant/sanitizer cleaner solution and an activator solution that are mixed together to form the alkaline in-use solutions. Disinfectant/sanitizer cleaner solution may comprise quaternary ammonium compound and hydrogen peroxide. Activator solution may comprise alkaline buffering agent, chelating agent and soluble silicon dioxide.

Abstract: The present invention is generally related to a lens care system and method for disinfecting and cleaning contact lenses. A lens care system or method of the invention is based on electrolysis of an aqueous chloride solution for generating germicide species (e.g., chlorine, hypochlorous acid, hypochlorite, or combinations thereof) and subsequent in-situ electrolysis of hypochlorous acid or hypochlorite in the aqueous solution for neutralizing the generated germicide species.

Abstract: The present invention relates to a liquid preparation for soft contact lenses, particularly hydrogel contact lenses or silicone hydrogel contact lenses. The liquid preparation for contact lenses according to the present invention contains a hydrolyzed hyaluronic acid derivative having a monoether of a linear or branched alkyl group or alkenyl group having 6 or more and 20 or less carbon atoms and glycerol in a side chain. The liquid preparation for soft contact lenses according to the present invention may contain at least one cationic bactericide selected from the group consisting of an alexidine salt, a chlorhexidine salt, a polyhexamethylene biguanide salt and a quaternary ammonium salt. The liquid preparation for soft contact lenses according to the present invention is capable of suppressing adsorption of a cationic bactericide to soft contact lenses, and suppressing occurrence of corneal staining in a wearer.

Abstract: The disclosure relates to polyurethane and polyureaurethane based putty compositions which harden into a fully cured solid form at room temperature and body temperature and are suitable for use as a bone cement, bone substitute, hard tissue adhesive, or bone hemostatic agent.

Abstract: It is disclosed a biocomposite of hydroxyapatite on graphene oxide sheets and its use for bone tissue engineering applications, such as bone repair, bone augmentation, as well as coating of biomedical implants. Processes for preparing said biocomposites are also described.

Abstract: The present invention provides a biocompatible hydrogel composition comprising glycolipids and silk fibroin (SF) wherein glycolipid is preferably sophorolipids (SL). The said composition is useful in preparation of 3D scaffold for use in tissue engineering, and in the biomedical field. The present invention also provides a process for preparing such a composition and a process for acceleration of gelation time of silk fibroin (SF) in the presence of sophorolipid.

Abstract: This invention relates to methods of producing collagen biomaterials by admixing (i) a solution of monomeric collagen, (ii) a solution of polymeric collagen, (ii) cargo particles, and (iv) a non-collagen blocking polymer, to produce a collagen solution. The collagen solution is then allowed to solidify to produce a collagen hydrogel. This may be useful in improving the stiffness of collagen hydrogel constructs and increasing the entrapment and retention of cargo particles.